To study the characteristics of off-label prescribing and adverse drug reaction (ADR) occurrence in a sample of pediatric outpatients treated by general practitioners.
WHAT'S KNOWN ON THIS SUBJECT: Off-label prescribing in children has been widely described. There has been growing awareness and action from regulatory bodies since 2006 to promote drug assessment in children and rational prescribing.
WHAT THIS STUDY ADDS:
In comparison with a similar study done in 2000, there was no significant change in off-label prescribing in children. In contrast with the previous findings, off-label prescribing did not increase risk for adverse drug reactions. Off-label prescribing has been widely observed in children. However, administration of a drug outside the conditions assessed during clinical trials may result in adverse drug reactions (ADRs). [1] [2] [3] Moreover, the specificity of children's physiology and pharmacology should not be neglected. 4 For years, the lack of drug evaluation in children has been evoked as a factor favoring off-label prescribing. More recently, 5 there have been several incentives to promote drug assessment in children, including promotion of good prescribing practice for antibiotics. In Europe, Pediatric Regulation No. 1901/2006 came into force in 2007. As stated by Lehmann, 6 "The Regulation (EC) No 1901/2006 sets up a system of requirements, rewards and incentives, together with horizontal measures, to ensure that medicinal products are researched, developed and authorised to meet the therapeutic needs of children." This regulation focuses on both public actors (European member states), encouraging them to promote research and pediatric drug availability, and pharmaceutical companies (incentives to conduct clinical trials in children). These actions tend to demonstrate that issues related to drug assessment and prescribing in children have raised awareness among policymakers. Despite regulatory differences, off-label prescribing is an issue in both the United States 7 and Europe. As a result of these initiatives, it may be hypothesized that prescribers would be more aware of the potential consequences of off-label prescribing, decreasing the prevalence of off-label prescribing and associated risks. 8 A study 2 performed in the early 2000s in France showed that off-label prescribing was highly prevalent (42%) and significantly associated with ADR occurrence. Since this period, in line with the promotion of drug evaluation and the development of new pediatric formulations, the situation is likely to have evolved.
To obtain an overview of the current situation 10 years after this study, 2 and considering that off-label prescribing in children has been poorly investigated in the ambulatory care setting, we designed a similar survey on the consequences of off-label prescribing in children. Our aim was to study the characteristics of off-label prescribing and ADR occurrence in a sample of pediatric outpatients treated in ambulatory practice. The study by Horen et al 2 was performed among pediatricians, whereas the current study was implemented among general practitioners (GPs). This difference reflects an evolution in pediatric practice in France, where ∼3 out of 4 children are currently referred to GPs. 9 This shift occurred in response to the decrease in the number of pediatricians in France. Difference in prescribing practices between French GPs and pediatricians have already been described. 10 Children treated by pediatricians receive fewer antibiotics than those managed by GPs but also fewer corticosteroids and significantly fewer antiinflammatory drugs. Expectorants and digestive motility drugs are also less likely to be prescribed by pediatricians than by GPs. 10 
METHODS

Study Design and Settings
A survey on pediatric drug prescribing was implemented in a sample of GPs from practices in the Midi-Pyrénées area (southwestern France). GPs were recruited from among those involved in the resident training program of the general practice university department. To be involved in resident training, they must have followed a complementary course organized by the department.
Participating GPs prospectively recorded information from all consecutive consultations involving patients aged 0 to 16 years for 1 week. Patient characteristics (age, gender, weight), main reasons for consulting, and drug prescribed (including dosage, route, and indication) were collected. GPs were provided forms that they completed electronically after each visit.
Children were categorized into 3 groups: newborn infants (0-27 days) and toddlers (28 days-23 months), grouped together because of sample size; children (2-11 years); and adolescents (12) (13) (14) (15) (16) , according to the International Conference on Harmonization guidance E11. 11 
Prescribing Patterns
To assess representativeness of prescribing patterns of participating GPs, we obtained data from the national health insurance database (Système National d'Information Inter Régimes de l' AssuranceMaladie) 12, 13 concerning all drugs prescribed and reimbursed for infants aged 0 to 16 years in the same area and during the study period. The health insurance database contains basic patient demographics, prescriber's specialty, drug prescribed, and quantity dispensed, but the indication is not available.
Off-Label Prescribing
Off-label prescription was defined as prescribing outside the specifications of the Summary of Product Characteristics (SPC) 14 , equivalent to the prescribing information in the United States. As was done previously, 2 off-label prescribing was defined according to 9 categories, including prescribing a drug withdrawn from the market, contraindications, different indications, age, different route of administration, higher dose or lower dose than recommended, and inadvisable coprescribing. To determine off-label status, we referred to the SPC. If the indication was not cited in the paragraph "Therapeutic Indications," the drug was considered off label for "different indication" (ie, unlabeled indication). However, for antibiotics, where the indication specified by the physician was a viral infection (rhinopharyngitis, laryngitis, tracheitis), the indication was considered labeled, with the assumption that the prescriber suspected a bacterial superinfection. To determine off-label dosage, we applied a 20% tolerance margin to the prescribed daily dose. For symptomatic treatments such as cough syrups, a lower number of doses compared with recommendations was not considered off label. For contraindications and inadvisable coprescriptions, we referred to the corresponding section of the SPC. Unlicensed drugs were those with no valid marketing authorization at the time of the study. Homeopathic preparations were considered products without license. Only 1 off-label category was assigned to each drug prescribed.
In case of multiple possible categories, the status leading potentially to more damage was selected (namely, by decreasing order of "priority": contraindication or different indication, age, route of administration, higher dose or lower dose than recommended, and inadvisable coprescribing). For all analyses, children were considered exposed to off-label prescribing if $1 of the drugs in the prescription form was off label. So even if children could potentially be exposed to $1 drug or $1 off-label drug, all percentages were calculated with the number of children as the denominator, including drug exposure and off-label drugs.
ADR Occurrence
Each GP was asked to identify and report to the regional pharmacovigilance center any ADR occurring #10 days after the date of consultation. ADRs were classified according to the Medical Dictionary for Regulatory Activities lower-level term and primary system organ class. All suspected ADRs were classified into 4 causality levels (ie, "possible," "plausible," "likely," and "very likely"), according to the French ADR causality assessment method. 15 A "serious" ADR was defined as "any untoward medical occurrence that at any dose results in death, requires hospital admission or prolongation of existing hospital stay, results in persistent or significant disability/incapacity, or is life threatening." 16 An "unlabeled" or "unexpected" ADR is a reaction whose nature or severity is not consistent with data contained in domestic labeling or market authorization or expected from the characteristic of the drug. 16 
Confidentiality and Ethics
During recruitment, GPs already involved in training residents were proposed to participate in this study by the general practice university department. Only 1 declined to participate. A written consent form was not required for GPs. All data were treated anonymously regarding the patients and GPs. Prescriber and patient IDs were assigned to match physician-child pairs. All ADRs were reported to the regional pharmacovigilance center, according to French pharmacovigilance good practices. 17 Access to reimbursed drug data on the health care database was allowed through authorization for evaluation of health care practices no. 1516745 of the French Data Protection Authority (Commission Nationale Informatique et Libertés).
Institutional review board approval was not required for this observational study.
Statistical Methods
Sample Size Calculation
According to the study performed in 2000 in the same area, 2 where 42.3% of patients were exposed to off-label prescribing, with a relative risk and ADR occurrence of 3.44, the sample size for the current study would have to be 922 patients to detect a risk increase of 3.44 in ADR occurrence with an 80% power (a = .05). 
Data Analysis
RESULTS
Children Characteristics
From March 8, 2011 to July 16, 2011, 2313 patients were recruited by 38 GPs. Among them, 1960 received $1 prescribed drug. All GPs prescribed $1 drug. Mean age was 5.6 years (SD 4.5, range 0-16), with a gender ratio of 1.1. Among the reasons for consultations (diagnosis, symptoms, or referral), diseases of the respiratory system (acute tonsillitis, n = 224; acute nasopharyngitis, n = 220), factors influencing health status (health checkup, n = 134; and immunization, n = 131), and symptoms (eg, fever) were the most commonly represented (Table 1) . Mean number of drugs prescribed was 2. Analgesics (52% ever exposed, n = 1003), antibacterials (22%, n = 422), and antiinflammatory and antirheumatic products (18%, n = 345) were most represented (Table 2) . Paracetamol, ibuprofen, and amoxicillin were most common.
Pattern of Prescribing From Health Insurance Data
In 2011, there were 2971 GPs and 125 pediatricians in the MidiPyrénées area. During the study period, 319 857 infants aged #16 years were reimbursed for $1 drug prescribed. GPs represented 77% of overall drug prescriptions (pediatricians 17%). To indicate the representativeness of prescribing patterns, drug classes from GPs in our study, together with those from GPs in the health insurance database, are presented Table 2 . Excluding analgesics (essentially paracetamol) that were less frequently prescribed than in our sample (37.7% vs 51.9%), prescribing patterns were quite similar, with the same prescribed Anatomical Therapeutic Chemical (ATC) classes in the top 5.
Off-Label Prescribing
Among the 1960 children receiving $1 drug, 37.6% (n = 736) were exposed to $1 off-label drug (638 with 1 drug, 94 with 2, and 4 with 3 off-label drugs) and 7.3% (n = 143) to $1 unlicensed drug. Off-label prescribing involved an unapproved indication in 56.4% (n = 416), a lower dosage in 26.5% (n = 195), a higher dosage in 19.5% (n = 144), age not labeled in 7.2% (n = 53), incorrect route of administration in 3.5% (n = 26), and contraindication in 0.3% (n = 2). Nasal decongestants (tixocortol, a corticosteroid, and tuaminoheptane, a sympathomimetic), H1 antihistamines (mequitazine, a phenothiazine derivative, and desloratadine), and corticosteroids (betamethasone and prednisolone) were the most frequently involved in off-label prescribing for indication. According to the SPC, tixocortol is indicated for nasopharyngeal inflammatory and allergic conditions (allergic rhinitis, seasonal rhinitis, acute and chronic congestive rhinitis, vasomotor rhinitis), whereas tuaminoheptane is approved for nasopharyngeal diseases with excessive mucus secretion in patients .15 years old. Tixocortol was prescribed with an unapproved indication for common rhinitis, whereas it is indicated only for allergic, congestive, or vasomotor rhinitis. Mequitazine and desloratadine were prescribed for cough, although they are indicated for the relief of symptoms associated with allergic rhinitis, urticaria, or conjunctivitis (mequitazine only). Prednisolone and betamethasone were prescribed with unlabeled indications for cough, bronchitis, or laryngitis. Drugs with lower dosage than specified involved mainly cold preparations (n = 24); ibuprofen (n = 20); helicidine, a cough suppressant (n = 19); and rifamycin for topical use (n = 17), whereas drugs with higher dosage than specified (n = 144) were represented mainly by tuaminoheptane (n = 39), phloroglucinol (n = 20), and amoxicillin (n = 17). When age was unlabeled (n = 53), antiinflammatory drugs (ibuprofen, diclofenac, and tiaprofenic acid, n = 12), antiinflammatories for topical use (diclofenac, niflumic acid, n = 7), analgesics (paracetamol and tramadol, n = 7), and antidiarrheals (medicinal charcoal, Saccharomyces boulardii, racecadotril, n = 6) were most frequently identified. An incorrect route of administration (n = 26) was encountered exclusively for vaccines and primarily (n = 23) for measles vaccine (in combination with mumps and rubella), which was administered by intramuscular injection, although the SPC recommend subcutaneous administration. Physiologic serum (n = 63) and oral rehydration solution (n = 13) (mainly for infants and toddlers) accounted for a large proportion of unlicensed drugs (n = 143).
Details of active substances and type of off-label prescribing are provided in Table 3 .
Determinants of Off-Label Prescribing
Determinants of off-label prescribing, identified through multivariate logistic regression, are presented in 
ADR Occurrence
Among children receiving $1 drug, 23 presented with $1 ADRs (27 described). The most frequently reported were fever (30.4%; n = 7), diarrhea (21.7%; n = 5), and erythema (21.7%; n = 5). Thirty-four different medications were involved (same active substance or fixed combinations), mainly antibacterials (n = 14; 41.2%) and vaccines (n = 13; 38.2%). After causality assessment, 11 (32.4%) were scored "possible," 16 (47.1%) "plausible," and 7 (20.6%) "likely." All ADRs were labeled, except 1 (erythema with sun exposure, caused by amoxicillin). Evolution was favorable in all cases. None of the ADRs were considered serious, and all were reported to the regional pharmacovigilance center.
Relationship Between Off-Label Prescribing and ADR Occurrence
Off-label prescribing was identified in 5 of 23 cases and involved prescribing for an unapproved indication in 3 cases (hydroxyzine and mequitazine for pruritus, betamethasone for pneumopathy) and an inadequate dosage of amoxicillin for the 2 remaining cases. Incidence of ADRs was 1.5% (11 in 736) for patients exposed to $1 off-label prescription and 1.0% in other patients. ADR occurrence was not related to off-label drug prescribing (crude OR 1.53; 95% CI, 0.67-3.49; P = .310). Multivariable analyses did not reveal significant associations.
DISCUSSION
Despite the numerous initiatives implemented since 2006 to promote rational medicine use in children, off-label prescription in outpatient pediatric practice remains high (37.6%). However, in contrast to the findings of a previous study conducted .10 years ago, we did not find an increased ADR risk related to off-label prescribing.
Strengths and Limitations
One of the strengths of this study is its prospective design, enabling us to study the incidence of ADRs in our sample. We were able to record more detailed information on exposure to medications than in retrospective studies of medication use reported by parents or relatives. Moreover, unlike in studies performed on reimbursement databases, data on indications were available in our study, which permitted us to better characterize off label prescribing in several categories (eg, contraindication, different indication). This study is also one of the few studies in outpatient settings published since implementation of Pediatric Regulation No. 1901/2006. To assess representativeness of prescribing schemes, we compared data from reimbursement claims with prescribing patterns in our study. They exhibited strong similarities, except for paracetamol, which is not systematically reimbursed. Because participation was voluntary, the possibility of selection bias among GPs should be discussed. They were all involved in resident training and thus likely to be more aware of off-label prescribing, resulting in a possible underestimation of the real incidence. Concerning the completeness of ADR data, the possibility of underreporting should be considered very low, and serious ADRs would have been detected, because GPs are systematically informed in cases of hospitalization. Total exposed: number of patients exposed to the corresponding substance. Number off label: number of patients exposed to $1 off-label prescription for the corresponding substance.
Studies of Off-Label Prescribing in Outpatient Settings
The study performed in the same region in 2000 among pediatricians 2 showed 42% off-label prescribing. When we compare diagnosis profiles, respiratory symptoms are still the most common but with a lower prevalence (38.7% vs 56.5% in 2000). Symptoms (eg, fever) were more common in our study (16 [20] [21] [22] on prescription databases revealed high off-label rates, from 13.5% to 62%, except an Italian study 23 with a 3.3% rate. This heterogeneity in results could be explained by differences in off-label definitions. To ensure comparability, we use the same definitions as in our previous study. 2 The most frequently retrieved classes of off-label prescriptions were nasal preparations (tixocortol, tuaminoheptane), H1 antihistamines for systemic use (mequitazine, desloratadine), and antibacterials (amoxicillin). In the study by Horen et al, 2 corticoids and b 2 mimetics for bronchiolitis, decongestants for rhinopharyngitis, and drugs from "blood forming organs" (prescribed to reinforce immunity in infectious ear, nose, and throat diseases) were the most frequently prescribed off label.
In the Swedish study, 22 off-label prescribing involved mainly topically administered drugs, sex hormones, antidepressants, hypnotics, cardiovascular drugs, and nonsteroidal antiinflammatory drugs. The most common classes in the Italian study 23 were antibiotics and drugs for the alimentary tract, metabolism, and the respiratory tract. However, the age groups were not strictly similar; the Swedish study 22 a Other diagnoses: blood, endocrine, nutritional and metabolic diseases, mental and behavioral disorders, nervous system, circulatory system, genitourinary system, and conditions originating in the perinatal period.
exposed to tixocortol, exhibited a lower rate of unlabeled indications related to this drug.
Studies Investigating ADR Occurrence in Outpatient Settings
Incidences observed in our study appear to be consistent with those reported in outpatient settings. 8 In 25 As concluded in the review from Mason et al, 28 it seems that there is no consistent evidence suggesting a greater risk related to off-label prescribing, perhaps because of the heterogeneity in prescribing settings or practices considered in the studies. Indeed, some studies found high rates of off-label prescribing of mental health or cancer medications. 22, 26 The risk reported by Bellis et al becomes not statistically significant when oncology patients were excluded from the analysis. In our study, GPs were not treating children with severe mental health problems, cardiac diseases, or cancer. It is therefore possible that ADR risk increases mainly with specific types of off-label use.
Perspectives
Unapproved indications were the main motive for off-label prescribing.
In another study, underdosing was more represented. 19 Beyond this observation, more information about the underlying causes of off-label prescribing is needed. In the present study, individual factors related to the number of medications or certain medical conditions were found to be associated with off-label prescribing.
Other factors have already been highlighted. 29 Determinants related to prescriber have also been described, such as lack of training or information. Moreover, it is generally believed that off-label prescribing is prompted by the unavailability of pediatric formulations. The typology of off-label prescribing for unapproved conditions tends to reveal the limitations of the prescribers' choices, because it involved indications that were closely related to the labeled indications (salbutamol for bronchospasm in the context of infection, where asthma is the labeled indication).
Since the implementation of the first pediatric investigation plans in 2007, 30,31 only a small proportion of the drugs frequently prescribed off-label have been covered by this regulation. Thus, the rate of off-label prescribing, even if not associated with ADR occurrence, should prompt more efforts to promote rational drug use and achieve change in prescribing patterns. 32 Recently, the new policy statement from the American Academy of Pediatrics on off-label prescribing 7 recommended that "the use of a drug, whether off or on label, should be based on sound scientific evidence, expert medical judgment, or published literature whenever possible." This study was performed in a European context, and some drugs are not in general use in the United States (eg, helicidine, phloroglucinol, tiaprofenic acid). However, these drugs were neither the most commonly used nor the most involved in off-label prescribing.
Most of the drugs prescribed off label in the current study are used worldwide, and possible crossnational differences in the availability of some drugs are not likely to affect the relevance of our findings for pediatric practice. This study provides additional scientific evidence on off-label drug prescribing in a setting that was poorly investigated in the literature, and therefore it may be useful for both clinicians and policymakers.
CONCLUSIONS
Despite the numerous initiatives implemented since 2006 to promote rational medication use in children, the prevalence of off-label prescribing in outpatient pediatric practice remains high. In contrast with the findings of a previous study conducted .10 years ago, we did not find greater ADR risk related to off-label prescribing. AIRPORTS AS DESTINATIONS: I spend a fair amount of time in airports -not necessarily by choice. I usually depart from Burlington International Airport as it is only 20 minutes from my home. As most travelers at the airport are either beginning or finishing their travel plans, the airport has few diversions for delayed passengers (although there are places to breastfeed and do yoga while you wait). Unfortunately, any weather disturbance on the mid-Atlantic seaboard can lead to outbound flight delays -not because of problems at our airport but because of air traffic holds. I now know the coffee shop extremely well, and the very best spot for Wi-Fi service.
As reported in The Wall Street Journal (The Middle Seat: November 12, 2014), the experience for travelers at other airports, particularly in the Persian Gulf, is remarkably different. Airlines and conglomerates have made the airports themselves destinations packed full of diversions such as theaters, museums, boutique shopping, swimming pools, and health spas. Amazingly, at least to me, some travelers eschew direct flights to their destinations and deliberately schedule stop-overs in these new airports. Their logic is that the entertainment and adventure at the airport is part of the fun. Business travelers enjoy the opportunity to unwind, dine, and shower in comfort. Vacationers enjoy the distractions that keep adults as well as children entertained. Business leaders hope that the increasing amount of airline traffic will spur economic development. So far, the model has worked with more and more flights landing at airports in the region. Airports in the area continue to expand, with one planning to build a terminal that can accommodate 200 million passengers a year -which is five times that of Chicago's O'Hare Airport. As for me, whether I am stranded in the Burlington or Philadelphia airport, my main concern is simply getting home. I am not yet ready to make the airport my vacation destination, but who knows? I might really enjoy a quick game of squash between flights.
